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Abstract 
Male Sprague Dawley rats implanted with bipolar stainless 
steel electrodes aimed at the medial forebrain bundle at the level of 
the hypothalamus were trained to self administer a rewarding 
current on a 20:10 DRP operant schedule. A procedure based on the 
psychophysical method of limits was used to determine the threshold 
of self administration for this stimulus. The effects of the B2-agonist 
albuterol (salbutamol) on threshold, rearing, and motor activity were 
examined prior to and after a 19 day period of daily administration 
of either desipramine 10 mg/kg, fluoxetine 10 mg/kg, or saline. 
Acute administration of albuterol 10 mg/kg caused a 
significant increase in thresholds and decrease in motor activity and 
rearing when compared to the three saline days prior to and post 
administration. Rats tested after 19 days of receiving desipramine 
daily or saline showed a similar increase in threshold when dosed 
with the albuterol 10 mg/kg while the group treated with fluoxetine 
10 mg/kg daily did not. The albuterol caused a pronounced drop in 
motor activity and rearing regardless of prior chronic drug 
treatment. These results are consistent with a down regulation of 
B2-receptors by chronic administration of fluoxetine but not by 
desipramine or saline. 
Acute administration of desipramine, fluoxetine, or saline did 
not cause any change in self stimulation threshold, though decreases 
in horizontal motor activity were seen with the antidepressants but 
not saline. Chronic daily administration of these antidepressants for 
19 days resulted m a decrease m motor activity over time as 
compared to the saline treated animals. However, thresholds for 
rewarding stimulation were not affected by chronic treatment with . 
an ti. d~pre i; s ant. 
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Preface 
The study descibed was undertaken in order to examine the 
effects of acute and chronic administration of antidepressants on 
reward capacity and motor activity in rats. Additionally, the effects 
of the B2-adrenergic agonist albuterol was examined in order to 
determine its effect on reward capacity and on motor activity. 
Finally, the potency of the B2-adrenergic agonist albuterol in 
changing thresholds and motor activity after chronic treatment with 
antidepressants was studied in order to see if B2-adrenergic receptor 
down-regulation caused by the antidepressants fluoxetine and 
desipramine was evident in lessened response to the B2-adrenergic 
agonist. 
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INJROPUCTION 
Overview 
The fortuitous discovery that the antitubercular compound 
iproniazid was an effective antidepressant led to the widespread 
application of congeners in treating individuals with major 
depressive disorders. These compounds all possessed the ability to 
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block the enzyme monoamine oxidase, which resulted in a buildup in 
nerve synapses of dopamine, norepinephrine, and serotonin. Due to 
the high potential for serious side effects with antidepressants of the 
monamine oxidase inhibitor type, a search began to find an equally 
effective antidepressant compound that did not possess the side 
effect profile of the monoamine oxidase inhibitors. This resulted m 
the discovery that compounds which inhibit presynaptic reuptake of 
norepinephrine (NE), dopamine (DA), and 5-Hydroxytryptamine (5-
HT) and thus effectively increase concentrations of these neuro-
chemicals in the synapse were also therapeutically effective 
antidepressants. Many such compounds were synthesized and 
marketed, with minor modifications yielding compounds with 
modestly different side effect profiles. These events led to a general 
acceptance that increase in synaptic levels of NE, DA, and 5-HT was 
necessary for antidepressant activity. Since some drugs which were 
similar in neurochemical profile to established antidepressants were 
also effective, compounds were routinely screened for such activity 
as a prerequisite for further testing. 
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Also useful in the quest for safer and more effective 
antidepressants are animal models, many based on behavioral 
foundations unrelated to theoretical underpinnings of proposed 
neurochemical mechanisms of action. The success of some of these 
techniques in developing pharmacologically unique compounds raises 
important questions as to what physiological effects are key to 
antidepressant activity. Assumptions as to the mechanism of action 
of antidepressant drugs were made because those studying the 
effects of these compounds on behavior could not identify what 
physiological changes were responsible for the behavioral effects. 
Attempts to do so related the effects of these drugs on such non-
specific brain areas as "whole cortex" to a grossly observable 
behavioral change, such as rat immobility, that can only be linked by 
a tenuous theoretical net to human depressive disorder. Missing 
from investigations in the area is the concept of a neurobehavioral 
network; that is , a physiological model that links neurochemical 
events to change in discrete brain regions associated with predictable 
changes in behavior. 
The need for a technique that tests the effects of drugs on a 
neurobehavioral network is behind our laboratory's examiPation of 
the intracranial self-stimulation (ICSS) model as a possible tool for 
understanding the mechanism of action of antidepressant drugs. The 
basic building blocks of animal and human behavior, reward and 
aversive stimuli, can be studied in relation to physiology in an in 
vivo preparation. The relationship between a drug's effect on a 
neurobehavioral network and the relationship of that effect to other 
behavioral and neurochemical changes can be examined. 
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Theories of the Mechanism of Antidepressant Action 
Catecholamine Hypothesis 
Theories for the mechanism of action of antidepressants are based 
on what neurochemical activities are common to most effective 
antidepressant drugs. One such activity is the ability of these 
medications to increase the amount of catecholamines available to 
the post synaptic cleft by inhibiting reuptake mechanisms. In 
contrast, medications which deplete presynaptic stores of 
catecholamines (eg. reserpine) can induce major depression in a 
substantial proportion of individuals. These two facts led to the 
development of the first theory of the biochemical basis of 
depression, the catecholamine hypothesis. Simply, a decrement m 
the amount of available catechoamines such as norepinephrine or 
dopamine or the indolamine 5-hydroxytryptamine in the synaptic 
cleft of brain regions, especially those linked to mood or motor 
activity, is associated with the development of depressive symptoms. 
Drugs which cause a reversal of this situation, such as the tricyclic 
antidepressants or monoamine oxidase inhibitors, are therapeutic 
(Cooper et al., 1986). 
Unfortunately, the catecholamine hypothesis is not consistent 
with other key properties of antidepressants. For example, it fails to 
account for the discrepancy between the immediate increase in 
synaptic catecholamine levels and the one to three weeks of 
treatment required for these medications to show clinical effects. 
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Also, some medications which also increase the availability of these 
transmitters, such as D-amphetamine or L-dopa, are acutely 
euphorogenic but are not useful in treating depression (Cooper et al., 
1986). Finally, the discovery of agent\\ th~t cio not cause an increase 
in synaptic catecholamines but are effective antidepressants (Shopsin 
et al., 1981) led to even more doubt as to the validity of the 
catecholamine theory of depression. 
Adrenergic Receptor Subsensitivity Hypothesis 
A number of theories of the biochemical basis of depression 
evolved to explain these inconsistencies. One that appeared quite 
valid for a time was based on the finding that presynaptic alpha 
receptors, or a2-receptors, became desensitized after several days of 
tricyclic antidepressant (TCA) or monoamine oxidase inhibitor 
(MAOI) administration (Crews and Smith, 1978). It was thought that 
this was the critical mechanism underlying response to 
antidepressant drugs. This theory has the advantage of a temporal 
association between the neurochemical and the therapeutic changes 
induced by antidepressants. Also, the alpha adrenergic receptor 
blocker yohimbine abolished the chronic effects of the tricyclic 
antidepressants imipramine and nortriptyline in the Porsolt forced 
swim test (Zebrowska-Lupina, 1980). The discovery and clinical 
utility of effective antidepressants that do not have this 
pharmacological effect has caused this theory to fall into disfavor 
(Sellinger-Barnette, 1980). 
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The most plausible remaining theory of antidepressant activity 
is that it is the down regulation of B-adrenergic receptors in the 
neocortex that is critical to antidepressant activity. Sellinger-
Barnette (1980) demonstrated that a broad range of compounds that 
were effective antidepressants all caused the down regulation of beta 
adrenergic receptors in neocortex, whereas compounds which had 
some pharmacological similarities to these compounds but which 
were not effective failed to down regulate beta receptors. Gandolfi et 
al. replicated this (1983) experiment and found similar results, along 
with a decrease in the amount of cyclic AMP, the second messenger 
for many neurotransmiters. This effect occurs at fourteen days, 
which is the time when clinically effective antidepressants begin to 
work. Direct beta agonists such as albuterol (salbutamol) and 
clenbuterol have been found to be promising new agents in the 
treatment of depression, and would directly cause down regulation of 
these receptors (Simon et al., 1984 ). 
Approaches to Identifying Antidepressant Compounds 
Techniques useful in discovering new antidepressant drugs are 
employed to measure either behavioral or neurochemical effects of 
the compound. That is, a compound will be tested to see if inhibits 
MAO or blocks reuptake of catecholamines using biochemical assays, 
or it will be tested to see if an animal will perform a certain way in 
animal paradigm. The predictive validity is critical to the utility of 
the test; that is, the greater the association of effect in the model and 
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clinical utility, the better the test. Assumptions as to how the 
neurochemical or behavioral change relates to what may occur m 
human depression are generally speculative and not as critical to an 
industrial pharmacologist trying to identify useful antidepressants as 
to their predicative validity. 
Techniques Based on Neurochemical Activity 
Many animal models used for predicting the efficacy of 
potential antidepressant compounds are derived from the ability of 
the compound to enhance catecholamine functioning in the manner 
of the MAO inhibitors and tricyclic antidepressants. One of the first 
animal models of depression useful in developing antidepressants is 
based on the ability of antidepressant drugs to prevent the 
autonomic and behavioral effects of tetrabenazine or reserpine (Costa 
et al., 1960). Pretreatment with antidepressants prevent the 
reduced locomotor activity, ptosis, hypothermia, and catalepsy 
caused by reserpine or tetrabenazine. These agents induce 
depression in up to one-quarter of those receiving them for 
treatment of hypertension (Quetsch, R.M., et al., 1959), though others 
put this figure at five percent (Goodwin et al., 1972). It is thought 
that their ability to deplete synaptic stores of catecholamines is 
responsible for this effect. Thus, these compounds created the 
proposed neurochemical disorder as well as the clinical syndrome in 
many receiving the drug. In accordance with these premises the 
model has excellent face validity. 
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The reserpme or tetrabenazine antagonism model has some 
difficulties in terms of predictive validity. Some second generatio_n 
antidepressants such as mianserin, trazadone, and bupropion are not 
active in this model though they are effective antidepressants 
(Cooper et al., 1983). Methylphenidate and d-amphetamine are 
active whether they are given before or after the reserpine or 
tetrabenazine (Howard et al., 1981 ). Also, L-dopa, alpha-adrenergic 
agonists, beta-adrenergic blockers, and antihistamines are active in 
this model (Wilner, 1984). Therefore, the model does not exclusively 
detect antidepressant compounds even though it is based on the 
catecholamine hypothesis, and fails to predict the usefulness of the 
newer and safer generation of antidepressants. 
Other tests based on the catecholamine hypothesis are the L-
dopa potentiation test and the D-amphetamine potentiation test. 
They share the drawbacks of the reserpine-tetrabenazine 
antagonism model and suffer even greater problems with face 
validity (Wilner, 1984). For example, pharmacokinetic effects result 
in the ability of antidepressants to potentiate amphetamine, with 
impairment of metabolism of amphetamine by the liver being the 
likely reason for the effect (Sulser et al., 1966). In short, these 
models yield many false positives and have failed to predict the 
efficacy of many novel antidepressants . 
Animal Models Based on Behavioral Theories of 
Depression 
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AniMa1 ~ models of depression are critical to the development of 
safe and efficacious drugs for the treatment of human depressive 
disorders (Cooper et al., 1983). The mechanism of action of 
antidepressant compounds is still unknown, and we are still quite 
dependent on these models for the development of new 
antidepressant compounds. In the case of some novel "second 
generation" compounds, animal models based on behavioral theories 
have been useful for developing medications that are clinically 
effective, pharmacologically unique, but which lack many of the 
shortcomings of established medications (Shopsin et al., 1981 ). 
For example, the Porsolt technique for screening antidepressant 
compounds (Porsolt et al., 1978) is based on the theory of learned 
helplessness (Miller et al., 1977; Abramson et al., 1978); this theory 
links the exposure of an animal to inescapable aversive situations 
with depressive behavior. Porsolt's technique has rats placed in 
beakers of water, the level of which just higher than their ability 
to comfortably stand; the rats eventually cease struggling and 
become immobile. Later tests in the same animals show a drastically 
decreased amount of struggling than when they were first exposed to 
this situation. However, rats that were treated with effective 
antidepressant compounds would struggle for much greater periods 
when exposed to this situation than control animals. This simple 
technique requiring little equipment has been very successful in 
identifying effective antidepressants; some of these antidepressants, 
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such as bupropion, share none of the biochemical activities and little 
of the side effect profile of traditional antidt:(pressants (Shopsin et al., 
1981; Dufresne et al., 1984 ). Other methods based on the learned 
helplessness paradigm are affected similar]~, by antidepressants 
(Leshner et al., 1979). 
A Neurobehavioral Approach Using Self-Stimulation 
Techniques 
As we have seen, a drug can be shown to have a certain effect 
neurochemically in vitro, or on observed behaviors in animals and 
humans. All functional tests of these drugs are in some way affected 
by an end stage behavioral translation of the neurophysiological 
activity. However, there has been little effort towards understanding 
the activity of these drugs on isolated tissue systems. We have 
knowledge of functions of many brain areas, what their 
neurochemical systems are, and what happens if we destroy a 
neurochemical tract or lesion the tissue. However, we are not as sure 
as to how various psychoactive drugs affect different brain regions 
and how they may remedy psychiatric illness. A system for 
evaluating the in vivo processes of brain functioning and how this 
affects behavior would greatly aid researchers out of a "black box" 
approach to understanding how antidepressants physiologically act 
in treating depressive symptoms. 
The intracranial self stimulation model is an important first tool 
in that the effects of altering a neurotransmitter in a discrete brain 
1 0 
region or path can be studied. Furthermore, it offers a mechanism of 
looking at the relationship between the neurochemical changes, the 
neurological event, and behavioral change. The interrelationships 
between brain systems that affect mood, appetite, and motor 
activity, for example, can be elucidated so that more specific, less 
toxic drugs can be developed to treat depression and perhaps other 
diseases of brain and behavior. Finally, the end effect of drugs, such 
as the down regulation of beta receptors in neocortex, can be 
examined to see if they are responsible or coincidental to the 
therapeutic activity of the medication. 
The threshold method of the ICSS technique is a potentially 
useful tool for examining the neurobehavioral effects of psychoactive 
medications, and has already been very useful in understanding the 
mechanisms of action of drugs of abuse (Marcus and Kornetsky, 
1974; Kornetsky and Bain, 1982; Unterwald and Kornetsky, 1986; 
Izenwasser and Kornetsky, 1987). Kornetsy has demonstrated 
repeatedly that the administration of drugs of abuse to rats causes a 
lowering of the pleasure threshold. That is, a drug such as morphine 
or amphetamine will cause an animal to work for a smaller amount 
of electrical stimulation than prior to receiving the drug (Kornetsy 
and Bain 1982; Hubner et al., 1987). Drugs that are self administered 
by humans in combination tend to potentiate each others 
euphorogenic effects (Unterwald and Kornetsky, 1986; Hubner et al., 
1987). 
ICSS techniques: Understanding the neurophysiology of 
reward and depression 
Depression as a Reward Deficit Syndrome 
1 1 
Stein (1962) advanced the theory that depression occurred as the 
result of insufficient positive reinforcement. According to his theory, 
while most of us exhibit some depressive symptoms during periods 
of low positive reinforcement, depressives tend towards despair 
even when their environment is sufficiently rewarding. He noticed 
in his work in stimulation of reward areas of the midbrain 
tegmentum that the drugs that were psychostimulants reduced the 
amount of current the rats would work for, whereas the dopamine 
depleting drug reserpine and haloperidol, a postsynaptic blocker of 
DA, increased the amount of current necessary for self stimulation 
response or even completely interfered with responding. The animals 
receiving the antidopaminergic agents did not show motor 
impairment. Imipramine did not lower ICSS thresholds on its own 
but did potentiate the effects of amphetamine on responding. 
Olds, the originator of the self-stimulation technique, believed 
that the brain was organized along hedonistic principles. He asserted 
that not only interneurons but specialized cell groups were part of a 
reward pathway which related to basic drives such as drinking, 
feeding, and mating, and that these systems were critical in 
reinforcing behavior necessary for survival (Olds and Fobes, 1981 ). 
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Current thinking is that the principle reward pathway is the neural 
tract which originates in the dopaminergic neurons of the ventral 
tegmental area (AlO) and projects to the limbic forebrain region via 
the mesocorticolimbic system (Fallon, 1988; Fibiger and Phillips, 
1988). Interestingly, major depressive syndrome involves not only 
anhedonia, but also the so called vegetative symptoms such as 
psychomotor retardation, decreased appetite, insomnia, and 
diminished sex drive. Anhedonia, the decreased capacity to 
experience pleasure, can be understood as due to hypoactivity of the 
central reward pathways. The vegetative symptoms can be 
attributed to the resulting decrease in basic drives. 
Early Attempts to Measure Reward Using Rate 
Techniques 
The ICSS procedure involves an animal self administering small 
amount of electrical current to discrete brain regions through 
implanted bipolar electrodes. The pioneering work on this procedure 
was done by Olds (1962). He demonstrated that rats would perform 
tasks, such as pressing a lever, to receive minute amounts of electric 
current applied to neurons in the lateral hypothalamus. Later work 
has examined the effects that psychoactive drugs have on rates of 
responding to different levels of brain stimulation via implanted 
electrodes in both reinforcing brain regions such as the lateral 
hypothalamus, ventromedial tegmentum, substantia nigra, and 
medial forebrain bundle (Kokkindis and Zacharko, 1980; Leibman, 
1983 ), and in areas where rats work to avoid the stimulation such as 
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certain reticular areas (Carr and Coons, 1981 ). The location of these 
sites associated with reinforcing electrical stimulation were along 
those nerve tracts associated with dopamine (DA) and 
rwrep~nep~rine (NE) neurotransmission. 
A principal area of interest was how drugs would affect reward 
or aversion. Investigators would test to see if various psychoactive 
substances would increase or decrease rate of response to receive 
rewarding stimuli (positive reinforcement) or to avoid aversive 
stimuli (negative reinforcement). The use of these techniques often 
resulted in interesting findings. For example, Olds and Olds (1964) 
tested the effects of chlorpromazine, amphetamine, mebrobamate, 
and LSD-25 on rate of response to rewarding stimulation of the 
lateral hypothalamus and avoidance of aversive stimulation of the 
tegmentum. They found that chlorpromazine depressed rates for 
positive reinforcement in doses that spared negative reinforcement, 
while the reverse was true for mebrobamate. Thus, these agents had 
specific effects on reward and aversion capacity unrelated to the 
decrease in motor activity caused by these medications. However, 
often conflicting results would appear for many other medications. 
For example, studies of the effects of morphine on rate of 
responding for rewarding stimuli would often be contradictory. In 
fact, some investigators found variable effects depending on dose 
and time after administration (Lorens, 1972 and 1976; Adams et al., 
1972). Lorens found a suppressive effect on rate of responding for 
rewarding stimulation of the lateral hypothalamus and the medial 
frontal cortex one hour after administration, variable effect at 3 
hours, and increased responding at 5 and 7 hours after morphine 
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given at 3.75, 7.5, and 15 mg/kg doses via LP. route. Pert and 
Hulsebus (1975) found only an increase in rate with morphine 
sulfatelOmg/kg given 3 hours prior to self-stimulation testing. 
However, consistent results appear in the ljterature when threshold 
techniques which are less affected by morphine's motor effects are 
used. For example, Kornetsky and associates have found repeated 
lowering of self stimulation thresholds with morphine at between 4 
and 16 mg/kg LP. in the rat (Marcus et al., 1974; Esposito and 
Kornetsky, 1977; Kornetsky et al., 1979; Hubner et al., 1986; 
Izenwasser and Kornetsky, 1987). Unlike the rate techniques, the 
threshold method seems less confounded by the motor effects of 
psychotropic medications. 
Rate Independent Techniques 
Investigators who used rate of responding per unit ampere or 
volt as their dependent variable often found their results were 
confounded by the sedative property of many drugs which are self 
administered. For example, barbiturates, narcotics, and 
benzodiazepines tend to cause motor slowing although the amount of 
current the animals will work for is decreased. Drugs which increase 
motor activity such as amphetamine also were difficult to assess 
accurately using rate techniques because of the difficulty in 
discriminating whether an increase in rate was due to the general 
stimulant effects of the drug or an increase in the reward value of 
the electrical stumuli. Thus, the results of studies based on rate of 
response per unit current often conflicted with each other (Olds J ., 
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and Travis R.P.; 1959, others) as well as with studies which 
attempted to control for the motor effects of the drugs being tested. 
Stein (1962) made one of the first attempts to study drug 
effects free of the performance confound. He used a two lever setup 
in which the animals could self regulate their current intensities. 
The animals would self administer current using one lever. The 
current would be gradually stepped down. The second, reset lever 
would be hit by the animal when the current level was judged by the 
animal to be insufficiently rewarding. Thus, this technique can be 
seen as a optimal current for reinforcement technique. The optimal 
current level at which the animal will still work is theoretically 
independent of the animals level of motor activity. 
Another technique designed to improve on the rate only 
methods is the rate-intensity function method (Fibiger and Phillips, 
1981; Leith and Barrett, 1981). In this method current levels are 
gradually stepped down until the animal stops responding and then 
increased until the animal once again is at the starting intensity. 
Rate of response is measured for each equal time interval and a rate-
intensity curve is plotted with intensity of current (or voltage) on the 
X-axis and rate of responding on the Y-axis. This method has the 
advantage of enabling the experimenter to examine the response 
over all current intensities. However, it is difficult to analyze 
responses using group statistics since the animals perform over such 
a wide range of current levels. Fibiger and Phillips (1981) got 
around this problem by looking at current levels at half maximal rate 
of performance as the dependent variable and using these values to 
perform group statistics. This is an effective current for 50 percent 
response analogous to the ED 50 concept in a dose response curve. 
However interesting this technique may be, it still uses rate of 
response as a dependent variable and should be affected by motor 
effects of drugs. 
Key to research by Kornetsky and associates is the use of the 
psychophysical method of limits, which yields results that differ 
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from techniques based on rate of response. This technique measures 
the minimum current level at which an animal will reliably work. 
This current level is known as the threshold for response. The 
threshold obtained using this method is not significantly correlated 
with rate of response (Kornetsky, 1985). This differs from the rate-
intensity methods and the two lever method in that the dependent 
variable is a minimum intensity of current for which the animal will 
work and not an optimal level. Kornetsky and associates use a 
stepwise procedure in which current descends and ascends twice; the 
mean of these values is considered the threshold. It is not reported 
how the descending and ascending values relate to each other. 
The ICSS Threshold Procedure as an Animal Model of 
Depression 
In a comparison of the relative predictive, face, and construct 
validity of animal models of depression, the ICSS paradigm is 
considered to be a useful model of depression (Willner, 1984 ). Using 
microelectrode implantation in the A-10 region, drugs such as the 
antidepressant desip~amine have been shown to increase lever 
pressing per current level in rats treated with agent for fourteen 
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days prev10us to testing (Fibiger, 1981 ). Willner (1984) emphasized 
how the inability to experience reward rn the ICSS model has face 
validity in light of the inability of depressives to experience pleasure 
and reinforcement. The increase in somatic complaints in 
depressives could also be perceived as an increase in perception of 
aversive stimulation. The fact that ICSS rates can be controlled by 
many of the factors which control responding for natural rewards 
such as food, sex hormones, or water (Olds, 1958; Hoebel and 
Teitelbaum, 1962) reinforce the view that this model may indeed be 
examining the neurological basis of reward. 
Prior studies of Antidepressant Activity using ICSS 
Techniques 
Prior work in our laboratory is suggestive that the the ICSS 
threshold technique is sensitive to behavioral and pharmacological 
procedures that should lead to changes in hedonic tone. The Porsolt 
technique of behavioral despair has been used successfully to induce 
prolonged increases in ICSS reward thresholds in rats (Valentino and 
Dufresne, 1989; Manuscript in preparation); desipramine 10 mg /kg 
P.O. caused moderate but significant drops in reward threshold at 
day 6 to day 9 as compared to saline controls and rats treated with 5 
mg per kg of desipramine (Riccitelli et al., 1989). Lastly, we 
replicated in our laboratory the pronounced reduction in reward 
thresholds by morphine dosed at 6 mg/kg I.P. (Wilcoxon signed rank 
test, p <.05) previously demonstrated by Kornetsky's laboratory 
(Marcus and Kornetsky, 197 4). 
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Prior investigations into the effects of antidepressant compounds 
on self stimulation models suffered from two key methodological 
flaws. Many investigators who tested the acute effects of 
antide;m~:; ::: ants on intracranial self stimulation ignored the fact that 
these drugs never demonstrate their therapeutic effects acutely. Not 
surprisingly, these studies do not reveal an effect for tricyclic and 
monoamine oxidase inhibitor antidepressants (Binks et al., 1979; 
Stein, 1962). Another problem was the use of a rate dependent 
measure that could be confounded by motor stimulant or slowing 
properties unrelated to effects on reward systems. Fibinger (1981) 
found an effect of increasing rate of response per microamp 
associated with chronic but not acute desipramine (10 mg/kg /day 
over fourteen days) in animals implanted in the A-10 region 
dopaminergic cells of the ventromedial tegmentum. This effect 
occurred while current levels ascended but not in the descending 
segments. It is difficult to interpret this study in light of the 
conflicting results on the ascending and descending phases; it is even 
more difficult to say what effect any motor effects of the drug or 
fatigue had on his results. The psychophysical method of limits that 
we have adopted from Kornetsky is not contaminated by motor 
effects, since the threshold is determined by the lowest current level 
an animal will work for greater than half the time. What is 
important is whether an animal will respond 5 of ten times the 
stimulus is presented at a certain intensity; extra responses do not 
figure into the dependent measure. Since the animal must only 
make one response every thirty seconds , changes in rate of response 
or in coordination are not critical to the performance of the task. 
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The Experiments of this Dissertation 
The intent of these series of experiments is to examine the effect 
two antidepressants medications have on thresholds for self-
stimulation in the medial forebrain bundle at the level of the 
hypothalamus, and to examine the consistency of these effects with 
the beta receptor down regulation theory of antidepressant activity. 
Desipramine is representative of the noradrenergic reuptake 
inhibitors while fluoxetine is representative of the serotonergic 
reuptake inhibitors. Manipulations will be performed to see if the 
effect on beta receptors is key or coincidental to the effects observed 
on any thresholds changes for intracranial self-stimulation of the 
medial forebrain bundle at the level of the hypothalamus. The mean, 
descending, and ascending thresholds measured in volts are used as 
the dependent variables rather than the rate of response since this 
method is theoretically less affected by drug induced alteration m 
motor performance (Liebman, 1983 ) .- Other methods used to 
evaluate the effects of antidepressants in the past have used 
techniques in which the overall motor activity of the animal could 
cause the change in the dependent variable since they were rate 
dependent (Fibiger, 1981). While overall motor rate may be related 
in some way to the therapeutic effect of antidepressants, we believe 
the increased ability to be reinforced by pleasurable stimuli to be an 
integral part of these medications ability to reverse depressive 
states. Overall motor rate will be assessed on open field photocham-
ber for horizontal activity and rearing. An initial 15 minute 
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exploration period as well as a second 15 minute period which 
reflects solely motor behavior are examined. The relationship of the 
motor response rate to threshold are examined. 
The first component of this study is an attempt to determine if 
change in intracranial self stimulation (ICSS) thresholds for reward in 
the rat occurs with chronic treatment with antidepressants. The 
second component attempts to explore if such a phenomenon is 
consistent with subsensitivity of beta adrenergic receptors. My 
predictions were twofold. The first is that effective antidepressants, 
no matter what their neurochemical effects, will have in common the 
ability to lower intracranial self-stimulation thresholds after one to 
three weeks of administration in rats. Secondly, the administration 
of a beta agonist compound after three weeks of antidepressant 
treatment will counteract the effect of down regulation of beta 
receptors in animals with lowered thresholds; if a beta adrenergic 
effect is responsible directly for this lowering of ICSS thresholds, the 
animals treated with antidepressant will have a decreased response 
to beta agonist in comparison with the control group. 
Summary of the Hypothesis of this Study 
The hypothesis of this study are as follows: 
( 1) Antidepressants alleviate depression by increasing reward 
capacity. An increase in reward capacity would be reflected in lower 
ICSS thresholds. Unlike euphorogenic drugs which work immediately 
(i.e. morphine), antidepressants take a minimum of 7 to 14 days to 
have their effect; therefore, it would take take that long for the 
thresholds to be lowered. 
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(2) Effective antidepressants cause a decrease in beta receptor 
binding sites that is temporally associated with their clinical effect m 
humans (Cooper et al., 1986). Thus, B-adrenergic agonists should 
have the opposite effect and raise thresholds for intracranial self-
stimulation. If B-adrenergic subsensitivity is associated with 
lowered reward thresholds, then it is likely that B-adrenergic 
supersensitivity is associated with increased reward thresholds. 
Thus, the B-agonist albuterol given 10 mg/kg via lavage should raise 
thresholds for self-stimulation. 
(3) Chronic treatment with the antidepressants desipramine 
and fluoxetine causes B-adrenergic receptor subsensitivity. Since the 
threshold raising effect of albuterol is likely due to its B-adrenergic 
agonist activity, then B-adrenergic receptor down-regulation should 
decrease its effect on thresholds. Since chronic administration of 
antidep ~ sants causes a decrease in B-adrenergic receptor 
sensitivity, then such treatment should lessen the threshold raising 
effect of the B-adrenergic agonist albuterol when compared to those 
animals treated chronically with saline prior to the albuterol 
administration. 
(4) The threshold method that we have adapted from 
Kornetsky and associates is less sensitive to the performance 
confound than the rate technique for measuring reward capacity. 
Therefore, it should be possible to show a decrease in motor activity 
and either no chang~ in or an increase in reward capacity (a lowered 
threshold). Also, it should be possible to show a change in threshold 
without a change in activity. Finally, an increase m motor activity 
should not always be associated with a lowered threshold. 
METHODS 
Animals 
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Male Sprague Dawley Charles River bred rats, weighing from 
250 to 350 grams at the time of surgery, were used. Sufficient 
animals were prepared until 24 rats were evenly divided into the 
three treatment groups over the full course on antidepressant or 
saline treatment. They were housed in gang cages prior to and 
separately after their surgery. They were given free access to food 
and water, and their living quarters were on an 18 hours of light, 6 
hours of dark cycle. They were allowed one week to recover from 
surgery before training. 
Apparatus 
Initial training of the animals took place in identical operant 
chambers with dimensions of 23 cm by 21 cm by 20 cm and 
equipped with a 5.0 cm lever. Stimulation was a monophasic square 
wave (60 C.P.S. , 4 millisecond pulses for 0.5 seconds) delivered by a 
Grass S48 or S9 Stimulator. Assessment of the actual voltage 
delivered was monitored using an oscilloscope. After the animals 
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had begun to adhere to the desired fixed interval schedule they were 
trained in identical operant chambers controlled by an Apple II 
computer running a stimulator manufactured by Coulburn 
Instru:ncnts, Inc.. This automated system insures uniform and 
accurate trials. The electrical stimulus was a 500 millisecond train of 
60 C.P.S., 4 millisecond biphasic square waves of intensities ofl 00 uA 
per volt. Electrodes were bipolar stainless steel electrodes fully 
insulated except at the tip. The open field tests were done in a 
Columbus instruments opto-varimax and opto-vertimax photocell 
chamber. 
Implantation of E lee trodes 
The rats were anesthetized pnor to surgery with pentobarbital 
dosed at 50 mg/kg body weight. Bipolar electrodes were aimed at 
the medial forebrain bundle at the level of the lateral hypothalamus 
using stereotaxic instrument. The coordinates used to implant the 
electrodes, with the top of the skull level, were 2.5 mm posterior to 
bregma, 1.8 mm lateral from the midline suture, and 8.5 mm ventral 
from the skull surface. 
Procedure for Determining Thresholds 
The animals were first trained to self administer the electrical 
stimulation. Voltage was set at a reliable setting for the individual 
animal to continue self stimulation. Initially , a 1 :1 fixed ratio 
schedule was used . When animals reliably lever pressed 20 times a 
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minute for at least fifteen minutes, they were switched to a fixed 
interval training schedule in which an initial stimulation preceded a 
ten second period in which lever pressing yielded a stimulation. 
After the lever press or ten second", wl-i-i~Ji\'ver occurred first, the 
animal entered a 20 second period in which stimulation was not 
available. A lever press during this period caused the twenty second 
cycle to begin again. This operant schedule is referred to as a 
differential reinforcement of a particular schedule (DRP). The 
method of successive approximation is used to shape animals to this 
reinforcement schedule. 
After animals were trained to the aforementioned fixed interval 
schedule, their initial thresholds were determined using the Grass 
S48 stimulator. They were then transferred to a similar operant 
chamber that was controlled via a computer program which 
regulated the voltage and kept track of lever presses. 
The psychophysical method of limits was used to determine 
thresholds. In order for a level of voltage to be considered capable 
of maintaining self stimulation, an animal must have lever pressed 
for at least five of the ten times the stimulation was available. This 
would have resulted in a positive segment. Initially, the animal 
received a level of voltage known in the past to support the self 
stimulation. Then, voltage descended in 0.2 volt amounts every time 
an animal lever pressed at least five of ten times to receive the 
stimulus. Eventually, the animal reached a point where the voltage 
level was so weak that it was not sufficiently pleasurable to be 
reinforcing. When the animal did not lever press for at least five of 
ten times for the voltage level that was available, a negative segment 
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was said to occur. When this happened three consecutive times, the 
animal was said to have reached its descending threshold. At this 
point, voltage levels began to increase .2 volts at a time. When an 
animal lever pressed again five of the ten times the stimulus was 
available, then the ascending threshold had been reached. Two 
positive segments in a row were required for the ascending 
threshold to be reached. The mean of the descending and the 
ascending threshold was said to be the mean threshold of the animal. 
Animals prepared to respond on the DRP schedule were tested on 
the automated apparatus until their thresholds were stable. Stability 
was determined as variation in voltage level of less than or equal to 
.6 volts between three successive descending and ascending thresh-
olds and less than or equal to .4 volts between three successive mean 
thresholds. 
Drugs 
Prior to entering the chronic treatment phase, the response of 
the animals to an acute dose of 10 mg/kg albuterol on threshold was 
measured. Animals were then randomly assigned to three treatment 
groups of at least eight animals per group. These animals received 
1.0 cc/kg of isotonic saline vehicle administered daily via gastric 
lavage for one week prior to randomization to experimental 
treatment. Both the desipramine group and the fluoxetine group 
receive 10 mg/kg (1 mg/.lcc vehicle) for the next three weeks of the 
study . 
Desipramine was chosen for this study since it selectively 
blocks reuptake of norepinephrine into presynaptic cells (Cooper, 
Roth and Bloom, 1986). Fluoxetine was chosen as the alternative 
antidepressant due to its very specific effect of inhibiting the 
reuptake of serotonin into presynaptic cells (Fuller, 1987). 
Desipramine does not have active metabolites. The principal 
metabolite of fluoxetine, norfluoxetine, is also a serotonin reuptake 
inhibitor. Both compounds show very little antihistaminic, 
anticholinergic, and sedative properties as compared with other 
antidepressants. Desipramine has been shown to down regulate B-
adrenergic receptors (Minneman et al., 1979; Sellinger-Barnette et 
al., 1980; Enna et al., 1981; Stahl et al., 1987,). Fluoxetine has also 
been found to down regulate beta-adrenergic receptors in several 
different brain regions and does so in both subtypes of beta 
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receptors (Wamsley, 1987). However, other investigators have failed 
to observe this effect ( Mishra et al., 1979; Mobley and Sulser, 1981 ). 
The dose of desipramine is based on that found to be most effective 
m lowering thresholds using this procedure in a pilot study (Riccitelli 
et al, 1989). The dose of fluoxetine is based on those previously 
found most effective in several animal models of depression (Stark et 
al. , 1985) 
Albuterol was chosen for this study since it as well as clenbuterol 
had previously been shown to possess antidepressant properties in 
human trials (Simon et al., 1984; Lecubier et al., 1980). Both drugs 
are beta agonists that are relatively selective for B2-adrenergic 
receptors. It is reasonable to assume that beta agonists found to be 
effective antidepressants should affect the same receptor population 
27 
as other antidepressants. The dose of albuterol was chosen based on 
the results of Leibman's study (1984) of B2-adrenoceptor agonists. 
Measures 
The dependent variables for all phases of this study were the 
mean threshold, descending threshold, ascending threshold, and open 
field activity measures. Weight in grams was measured during the 
antidepressant test phase. The open field activity measures 
consisted of horizontal (lateral) movement and rearing (vertical) 
movement. These measures can be independent; DA agonists tend to 
increase rearing selectively where DA antagonists tend to decrease 
rearing. General central nervous system stimulants tend to increase 
horizontal motion, and the converse in also true with general 
sedatives. The motoric variables are assessed immediately after the 
threshold procedure. The first fifteen minutes of activity reflects 
behavior of an exploratory nature, whereas later activity such as 
during the second fifteen minute period in this study reflect a less 
confounded measure of general activity levels. For this reason, the 
two periods of measured activity will be viewed as reflecting 
predominantly exploratory or motor activity respectively. 
Study Design 
The first segment of this study examined the effects of the 
beta agonist albuterol on thresholds prior to and after the chronic 
antidepressant test period. The response of the animals to a single 
I 0 mg/kg dose of albuterol was measured prior to and after the 
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antidepressant treatment phase. The pre-antidepressant beta period 
was designed as follows. The rats received saline via gastric lavage 
daily for each test period until three consecutive stable thresholds 
occur. The rats then received 10 mg/kg of albuterol via gastric 
lavage. Thresholds were then recorded for three test days after the 
al bu terol treatment. 
The second segment of the study was the antidepressant phase. 
At least one week after receiving albuterol and following at least 
three consecutive stable baselines, the rats were randomly assigned 
to receive either desipramine lOmg/kg, fluoxetine IOmg/kg, or 
saline. The rats were tested three times weekly. On the twenty first 
day the animals received albuterol for the post treatment beta-
agonist challenge. The rats received the antidepressant or control 
doses after testing in the early evening; however, the initial dose of 
antidepressant or saline was given 30 minutes before threshold 
testing so that the effect of an acute dose antidepressant could be 
compared with results from other studies and with chronic effects. 
Since the first test day of the chronic period differs from the others, 
it was tested independently of the chronic treatments. The acute and 
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chronic effects of antidepressants versus control was considered as a 
second larger experiment 
The final part of this study occurs after three weeks of 
antidepressant treatment. Forty-e!ght hour~ ::\fter the last dose of 
antidepressant or saline animals were administered the beta-2 
selective agonist albuterol via gastric lavage at a I 0 mg/kg dose and 
tested for threshold and motor rate one again. If lowering of ICSS 
thresholds is a direct result of beta receptor down regulation, then 
the acute administration of the beta agonist should reverse the effect 
of the antidepressants. The change in threshold due to beta agonist 
challenge should be less than that observed prior to the 
antidepressant treatment. If the effect is indirect or not at all 
related to beta adrenergic receptors, then no reversal due to acute 
albuterol administration should take place. 
Statistical Analysis 
Data was analyzed for each of the phases using Multivariate 
Analysis of Variance (MANOV A) with repeated measures using the 
within contrast pooled technique (Winer, 1971; Davidson and 
Toporek, 1986). The only variable not analyzed using MANOV A 1s 
the mean threshold, which was separately analyzed via repeated 
measures analysis of variance in order to avoid collinearity with the 
descending and ascending thresholds. Significant MANOV A's for each 
phase are followed by separate repeated measure ANOV A for each 
dependent variable. Significant ANOV A were followed by tests of 
simple or simple main effects, with significant tests of simple effects 
being followed by contrasts of individual means using techniques 
consistent with hypothesis tested . 
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RESULTS 
Tests of Albuterol Effects Prior to Chronic Antidepressant 
Treatment 
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It was correctly predicted that the acute administration of the 
B-agonist albuterol (10 mg/kg) would raise thresholds for self-
stimulation. One-way repeated measures ANOV A showed a 
significant change over time for mean threshold (F=2.64, df=4, 108, 
p<.05). Contrasts show a significant difference between the two 
saline test periods prior to treatment with albuterol (F=4.65, df= 
1,27, p<.05) and between albuterol and the two saline test days 
following such treatment (F=4.34, df=l ,27, p<.05). The increased 
mean threshold in response to treatment with albuterol with the 
subsequent return to baseline can be seen in Fig. 1. 
The dependent variables measured and analyzed by a repeated 
measures one-way MANOV A were thresholds descending and 
ascending, and open field activity both horizontal and rearing 
(vertical) over the first and second fifteen minute periods. There 
was a significant difference over time (Wilks's Lambda = 0.4692, df= 
24, 304.72 , p< .001) for dependent variables measured. Follow-up 
ANOV A's demonstrate that there were differences over time for 
ascending threshold (F=8.05, df=l,27, p < .01), but not for descending 
threshold (Fig. 2). Contrasts show a significant difference for 
ascending thresholds between the two control test days prior to 
albuterol administration (F= 5.58, df= 1, 23, p < .05) and the two 
control test days after ( F=6.00, df=l ,23, p < .05). 
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Follow-up ANOVA's show that horizontal motion changed over 
time for the first fifteen minute reading (F=9.37, df= 4,92, p < .01) 
and for the second fifteen minute reading (F=6.62, df=4,92, p < .01 ) . . 
Con~ns~~ showed that the albuterol administration day differed from 
both the previous (F= 28.19 and 11.62, df= 1,23, p<.01) and 
subsequent (F= 35.92 and 6.81, df=l ,23, p < .05) control days for both 
time periods respectively. Rearing activity also differed over time 
for both the initial fifteen minute period (F=3.85, df=4,92, p < .01) 
and for the second (F=5.93, df=4,92, p < .01 ). The albuterol test day 
was once again different from the two control days prior (F=34.20 
and 36.73, df=l,23, p<.001) and post (F= 32.16 and 18.19, df=l,23, p < 
.001) for the first and second fifteen minute periods. The decrease m 
all motoric variables for both exploratory and general motor 
behavior are pronounced but tend to return to baseline following the 
albuterol test day (Fig. 3 to 6). 
The B-agonist albuterol caused increases m mean threshold and 
a generalized decrease in activity. This is consistent with the 
hypothesis that B-adrenergic receptor supersensitivity is associated 
with increases in threshold. However, since motor activity decreased 
along with reward capacity, it is impossible to rule out a decrement 
in performance as the reason for the increased threshold. 
Tests of Albuterol Effects After Chronic Antidepressant 
Treatment 
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Two separate comparisons are of impure here. First, does 
albuterol IOmg/kg cause a change on the dependent variables as 
compared to the last week of antidepressant or saline treatment, and 
secondly does any change due to albuterol differ from the three 
saline test days post administration. A decrease in B-adrenergic 
receptor sensitivity due to chronic treatment with antidepressants 
would lessen the threshold raising effect of the B-adrenergic agonist 
albuterol when compared to those animals treated chronically with 
saline prior to the albuterol administration. 
A comparison of the three last test periods of the chronic 
antidepressant phase and the final albuterol test day yields 
interesting findings. ANOV A on mean thresholds (Fig. 7) 
demonstrate a significant increase over time (F=8.48, df=3,63, p<.01) 
and for drug over time (F=2.54, df=6,63, p < .05). Tests of simple 
effects show that both desipramine (F=8.21, df=3,63, p < .01) and 
saline (F=5.01, df=3, 63, p < .01) treated animals show increased 
thresholds in response to albuterol while the fluoxetine treated 
animals do not. The albuterol test days was different than all three 
previous days (protected contrasts, df= 1, 7, p < .05) for both 
desipramine and saline. 
Repeated measures MANOV /"\ on the remaining variables (Fig. 8 
-14) resulted in a significant finding for change over time (Wilkes's 
Lamda = .2537, df=21,164.22, p <.0001) but not for drug by time. 
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Follow-up ANOVA's show a similar pattern of change over time 
(df=3,63, p < .01) regardless of drug group for descending threshold 
(F=4.95), ascending threshold (F=6.37), weight (F=l 7.49), horizontal 
movement over both fifteen minute periods (F=7.14 and 4.91), and 
for rearing over both periods (F=7.59 and 10.74). A significant result 
for mean thresholds and not for the descending or ascending 
threshold separately may be related to increased reliability or 
measurement with a decreased error term when using the average 
measure of threshold. 
Mean thresholds did not differ between the albuterol test day 
and the three control test days afterwards. MANOVA on the 
remaining dependent measures show a significant decrease from the 
albuterol test day to the saline days thereafter (Wilkes's Lamda = 
.1173, df=21,147, p <.0001) regardless of group membership. 
Follow-up ANOVA's show no differences for descending or ascending 
threshold from albuterol test day to the saline control days. The 
motoric measures differed over time without regard to group. 
Horizontal activity differed over time for the first (F=l6.61, df=3,57, 
p < .01) and second (F=l4.50, df=3,57, p < .01) fifteen minute periods 
as did rearing for both periods (F=l 1.13 and 12.84, df=3,57, p < .01). 
As the animals previously treated with antidepressants began to 
regain lost weight the ANOV A demonstrated a significant time 
(F=66.48, df=3,57, p < .01) and drug by time interaction 
(F=6.50,df=6,57, p < .01). 
The animals treated for nineteen days with fluoxetine 10 
mg/kg via gastric lavage did not show an increase in threshold upon 
administration of albuterol whereas those treated with desipramine 
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10 mg/kg or equal amounts of saline vehicle ove e same time 
period did show an increase in mean threshold upon albuterol 
administration. One possible interpretation is that the serotonergic 
antidepressant fluoxetine prevented threshold elevation upon 
administration of albuterol, while the noradrenergic antidepressant 
desipramine did not. An alternative explanation is that the 
desipramine and saline treated animals developed increased 
thresholds due to withdrawal of the daily evening injections. The 
later explanation would be in accordance with the continued 
elevation of thresholds after the albuterol test day. However, the 
lack of threshold elevation in the fluoxetine treated animals during 
this period is not explained by the alternative interpretation. 
Acute Antidepressant Phase 
As acute treatment with antidepressants does not result m 
therapeutic improvement in patients suffering from major 
depressive syndrome, it was not expected that thresholds would be 
altered by acute treatment with desipramine or fluoxetine as 
compared to saline when given thirty minutes prior to testing. The 
results of this study phase is consistent with these expectations. 
MANOV A on descending and ascending thresholds, motor 
activity variables, and weight demonstrates that there was a 
significant change over time (Wilks's Lamda = .5075, df=14, 72, p < 
.05) and significant change for drug by time (Wilks's Lamda = .3373 , 
df=14, 72, p < .05). There were no significant changes over time or 
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for drug by time for mean, descending, or ascending thresholds (Fig. 
15 - 17). There was a significant over time interaction for weight (F= 
11.20, df=2,42, p < .01) with all animals gaining weight (Fig. 18) 
during the control test days as would be expected. Follow-up 
ANOV A'S show significant differences on some motoric variables (Fig. 
19 - 22) for drugs over time. In the first fifteen minute exploratory 
phase there were significant differences for drug by time for 
horizontal activity (F=3.81, df= 4,42. p < .01) and for rearing (F=2.62, 
df = 4,42, p < .05) activity. A modest decrease in activity 
independent of drug treatment was also present (F=5.99, df = 2,42, p 
< .01). On follow-up tests of simple effects the desipramine treated 
animals show a pronounced decrement in horizontal motor activity 
(F=3.53, df= 2,42, p < .05) and rearing (F=6.ll, df=2,42, p < .01) for 
the first fifteen minute period whereas the fluoxetine treated 
animals only exhibited a decrease in rearing (F=4.89, df=2,42, p < 
.05). Curiously, the saline treated animals exhibited a significant 
(F=3.68, df=2,42, p < .05) increase in horizontal activity during the 
first fifteen minute test period. Follow-up contrasts (p < .05) 
demonstrate these significant effects to be a result of differences 
between the two control test days and the acute antidepressant 
treatment day. 
The results of ANOV A'S on the second fifteen minute period 
showed a significant drug group over time interaction for horizontal 
movement (F= 4.19, df = 4,42, p < .01) but not for rearing. Simple 
effects tests reveal that the desipramine (F=4.10, df= 2,42, p < .05) 
and fluoxetine (F=3.80, df=2,42, p < .05) groups had decreased 
horizontal motor activity over time whereas the saline group did not. 
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Follow-up contrasts show this difference to occur between the 
control days and the acute antidepressant treatment day (protected 
contrast, p < .05). 
The decreases in activity observed on the motoric variables 
was not associated with a concomitant increases in threshold; this 
lends support to a lack of confound between motoric and threshold 
effects. The significantly increased levels of lateral activity in the 
first fifteen minute period seen with the saline control group did not 
occur on any other tests of motor activity during the entire study 
and is thought to be the result of type I error. Simply, it is likely 
that for every twenty tests of statistical significance at an alpha level 
of p < .05, one will be statistically significant due to chance. A lack of 
alternative causes for this effect and the fact that opposite changes 
occurred in the treatment groups lend support to this conclusion. 
Chronic Antidepressant Phase 
This study phase was performed to test the hypothesis that 
antidepressants alleviate depression by increasing reward capacity. 
An increase in reward capacity would be reflected in lower 
thresholds for intracranial self-stimulation which would occur at 
least one week of chronic antidepressant treatment. However, the 
antidepressants desipramine and fluoxetine given 10 mg/kg via 
lavage daily for nineteen days did not lower thresholds as compared 
with saline. 
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For the descending and ascending thresholds, motoric variables, 
and weight there was a significant change oyer time (Wilks's Lamda 
= 0.4422, df =63, 1036.77, p < .0001) and for drug over time ( Wilks's 
Lamda = 0.1969, df= 126, 1212.07. p < .0001). Follow-up ANOVA's 
show that there was a significant increase in thresholds over time 
(Fig. 23 - 25) independent of drug treatment group for mean (F=2.96, 
df= 9,189, p < .01), descending (F=3.17, df = 9,189, p < .01), and for 
ascending thresholds (F=2.02, df = 9,189, p < .05). These findings 
indicate a gradual increase in thresholds irrespective of drug 
treatment over the 18 day period. 
ANOV A for weight showed a significant decrease in grams over 
time (F=3.34, df=9,189, p<.01) and for drug by time (F=14.23, 
df=l 8,189, p<.001). Tests of simple effects show that weight 
decreased dramatically in the desipramine (F= 9.23, df=9,189, p < 
.01) and fluoxetine (F=8.93, df=9,189, p < .01) groups (Fig. 26) and 
increased markedly in the saline group (F=13.64, df= 9,189, p < .01). 
Follow-up ANOV A for the first fifteen minute activity period 
shows that all groups decreased significantly over time for horizontal 
activity (Fig. 27) and rearing (Fig. 28). For the second fifteen minute 
period there was a significant drug by time interaction for horizontal 
activity (F=2.32, df=18,189, p < .01) and rearing (F=2.47, df=18,189, p 
< .01) as well as non-specific over time effect for rearing (F=l.50, 
df=9, 189, p<.01 ). Tests of simple effects show decreased horizontal 
activity (Fig. 29) for desipramine (F=2.68, df=9,189, P < .01) and 
fluoxetine (F=2.81, df=9, 189, p<.01 ), but not for the saline treated 
animals. Similarly rats administered desipramine (F=3.41, df=9,189, 
p< .01) and fluoxetine (F=3.05, df=9,189, p < .01) showed decreases in 
rearing activity (Fig. 30) while saline did not. Thus, drug induced 
decreases in motor activity after the exploratory period were 
pronounced. 
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The pronounced decreases in lateral and reanng activity were 
not associated with significant increases in threshold. This result is 
consistent with a lack of dependence of the threshold measures w.ith 
decreased motor activity. However, since changes in threshold did 
not occur without concurrent changes in motor activity of the 
opposite direction, the dissociation of these measures can not be 
entirely proven based solely on the result of this study. 
DISCUSSION 
Effects of Antidepressants on Self-Stimulation Thresholds 
Acute Phase 
As hypothesized, there were no effects of an acute dose of 
desipramine (lOmg/kg), fluoxetine (10 mg/kg), or saline on either 
mean threshold or its component descending and ascending 
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thresholds (Fig. 15-17). This is expected since antidepressants take 
a minimum of one to three weeks to exert their therapeutic actions 
clinically (Cooper et al., 1983). However, drugs which increase 
catecholaminergic activity tend to reduce reward thresholds 
(Kornetsky et al., 1979; Hubner et al., 1987) while agents such as 
reserpine (Stein,1962; Leith and Barrett, 1980) raise reward 
thresholds. This has led others to test for acute activity of 
antidepressants in intracranial self-stimulation. 
Binks (1978) and associates tested the acute effects of varymg 
doses of the tricyclic antidepressants imipramine and protriptyline 
on rates of self-administration of current on fixed interval schedules 
ranging from 9: 1 to 1: 1 ratios of response to reinforcement. The 
electrode implant was aimed at the medial forebrain bundle of the 
lateral hypothalamus as in the present study, and the rats were 
required to demonstrate two consecutive days of stable response 
baseline prior to receiving each dose of drug. The criteria for 
stability was not revealed in the report. Imipramine given 
subcutaneously in 3, IO, and 30 mg/kg dosages and similarly 
administered protriptyline (IO mg/kg ) did not cause significant 
differences from saline control over all fixed interval schedules. 
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However, D-amphetamine 0.5 mg/kg given subcutaneously resulted 
in significantly increased response rates which were most 
pronounced at the higher fixed interval ratios. These results are 
consistent with the immediate pronounced mood elevating effects of 
d-amphetamine not seen with antidepressants. 
Stein (1962) tested the effects of catecholaminergic drugs on 
threshold of self-stimulation to the lateral hypothalamus and 
midbrain tegmentum. He theorized that clinical depression was the 
result of insufficient positive reinforcement due to decreased 
catecholaminergic activity resulting in a hypoactive reward system. 
Rates of responding to gradually decreasing levels of current were 
recorded; a second lever was available to the animals which they 
would press to reset current to the highest level after the ever 
lowering stimulation level was no longer sufficiently rewarding. 
Methamphetamine and d-amphetamine caused lowering of reset 
value and rate, while reserpine and chlorpromazine had no effect on 
these parameters. Stein also tested an acute dose of imipramine 
IOmg/kg and found no effects on reset value or rate. However, he 
found that the same dose of imipramine potentiated the effects of d-
amphetamine on these measures. He found these results to be 
consistent with his understanding of the relation of catecholamines 
and the reward systems. He failed to address the lack of effect of 
imipramine in his paradigm even though it also acutely increased DA 
and NE levels in the synapse. 
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In Fibiger's study (1981) of the activity of desipramine on self-
stimulation of the dopaminergic A-10 region of the ventromedial 
tegmentum, an acute dose of the drug was also given. As in the 
previcus ::: tuc!ie:;, there were no acute effects of the antidepressant 
on rate or on a rate for current intensity curve. One early study did 
show an increase m response rate by imipramine in cats working for 
very low current stimulation of the lateral hypothalamus (Horovitz et 
al. 1962). It is unclear if this finding could be due to the difference 
in type of test animal. An acute study of the effects of fluoxetine on 
rate of responding for electical stimulation of the medial forebrain 
bundle showed a dose dependent decrease in rate with fluoxetine 
(Katz and Carrol, 1977); however, this effect was not observed in the 
present study and is likely an artifact of a decrease in motor activity 
reducing the rate of response without an actual change in reward 
threshold being present. 
Chronic phase 
In the rats given chronic daily doses of desipramine and 
fluoxetine there were no significant differences in mean, descending, 
or ascending thresholds as compared with the saline control (Fig. 23-
25). In fact, the thresholds of the antidepressant treated animals 
appear to be drifting upward relative to control. These results differ 
from prior studies of chronic antidepressant effects on self-
stimulation . 
A previous study performed in our lab did show a small but 
significant decrease in thresholds in rats given desipramine 10 or 20 
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mg/kg/day by lavage versus those given a 5 mg/kg day dose or 
saline (Riccitelli et al., 1989). The absolute difference was small (.4 
volt or 2 steps) when compared with control, especially compared to 
the pronounced decreases observed witP. !110rphine sulfate 6 mg/kg 
in our lab (Fig.31 ). Kornetsky has observed a similar dramatic effect 
in a threshold procedure with mood altering drugs such as morphine 
(lzenwasser and Kornetsky, 1987) and amphetamine (Kornetsky, 
1985). Also, this difference between desipramine and saline was 
enhanced by a gradual upward drift in thresholds by the control 
group over the three week period not observed in the desipramine 
10 and 20 mg/kg groups. Thus, this difference could have been a 
prevention of upward drift in self stimulation thresholds rather than 
a real decrease. Furthermore, the effect was very small as compared 
with the marked threshold lowering effects of euphorogenic drugs 
and therefore of doubtful value in significantly increasing the 
capacity for reward. 
Another possible explanation for the difference in result 
between the present and previous study is that the drugs were given 
one-half hour prior to testing throughout the chronic antidepressant 
period in the first study. In the present study we administered the 
antidepressants or saline after the animals had been tested such that 
it was always twenty-four hours after the last dose when the 
animals were tested. Since desipramine has a long half-life, takes at 
least a week of administration to be effective, and is likely 
dependent on subtle receptor changes for its therapeutic activity, it 
seems likely that any effect on reward thresholds would be more 
pronounced when not confounded by acute effects such as sedation. 
However, one cannot rule out that in the study of Riccitelli and 
associates the rats began to respond to the later doses of 
antidepressant via some form of sensitization such as reverse 
tolerance. 
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Both results differ from that of the most promising study 
performed examining the effects of chronic antidepressant treatment 
on self-stimulation. Fibiger and Phillips (1981) demonstrated that, 
after fourteen days of chronic daily injections with desipramine 10 
mg/kg, rats implanted in the A-10 region of the ventromedial 
tegmentum had an increased rate of self administration per unit 
current than controls and rats treated acutely with desipramine. 
However, this effect occurred only as stimulation intensity was 
gradually increased and not as it was decreased. The effect was 
largest at the point of half-maximal responding, with those animals 
treated chronically with desipramine responding at the same rate for 
26.35 percent of the current required at baseline and by the control. 
However, neither maximal rate of response nor response rate at the 
lowest current intensities which support self-stimulation were 
different between treatment groups. 
Fibiger and Phillips noted consistently higher rates of 
responding for the middle current intensities while stimulation 
intensities were ascending as compared to when they were 
descending. Koop (1977) previously demonstrated a similar positive 
contrast effect. An alternative explanation for the effect seen with 
chronic desipramine treatment on the ascending current intensities is 
that the antidepressant enhanced this positive contrast effect and not 
reward (Liebman, 1983). 
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An important difference between the study of Fibiger and 
Phillips and the present study is location of implant. The A-10 
region is a dopaminergic nucleus, whereas the medial forebrain 
bundle also contains noradrenergic and serotonergic fibers. 
Desipramine, a potent NE reuptake blocker, could have an indirect 
effect on A-10 via noradrenergic innervation or on DA metabolism. 
This effect might not be observed in the medial forebrain bundle 
where there is a more heterogeneous distribution of 
neurotransmitters and innervation (Cooper et al., 1983 ). 
Another possible explanation for the lack of effect of 
desipramine and fluoxetine on thresholds in our study is that 
antidepressants work to prevent or reverse abnormal raising of 
reward thresholds without having any threshold lowering effects m 
animals already at normal reward capacity. The analogous situation 
in humans is that antidepressants work to abolish or prevent 
depression but have no euphorogenic effects in man. This is 
consistent with current knowledge of antidepressant therapy; that is , 
they are effective in reversing depression after two or three weeks 
in many patients but are not abused for euphorogenic effects. While 
it is possible thi is because addicts typically lack the patience to 
abuse a drug with many side effects for two weeks or more to get an 
effect, a lack of euphorogenic effects is consistent with the frequent 
lack of compliance seen with antidepressant drugs. 
A study in mice that supports this notion is that of Zacharko 
and associates (1984). They demonstrate that mice given 
uncontrollable foot shock show a pronounced decrease in rate of self-
stimulation of the nucleus accumbens for up to at least one week 
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after stress situation. Control mice and thosP treated with 
desipramine 5 mg/kg do not show this prolonged reduction in 
threshold. Interestingly, the desipramine treated animals show the 
same response to shock as the saline treated animals immediately 
after the stress situation, but not at I and 7 days. Also, a trend for 
somewhat increased rate of response for both desipramine groups in 
comparison to saline control is evident between day 1 and day 7 for 
both shock conditions. However, a comparison of the shocked 
animals shows a three fold greater response in the desipramine 
treated animals as compared to saline control. Therefore, it seems 
possible from this study, and consistent with clinical experience, that 
antidepressants require that the reward capacity be abnormally low 
to show a pronounced effect. This is in contrast to drugs such as 
morphine or d-amphetamine, which cause pronounced decreases m 
reward threshold even if an animal is already functioning at a 
normal level of reward capacity. Also, this view is consistent with 
the ability of antidepressants to prevent relapse of depression in 
humans. 
To treat mood disorders, it is imperative to restore the normal 
capacity of the reward system without causing instability. D-
amphetamine increases reward capacity immediately and 
dramatically, yet it is not 11seful therapeutically in affective disorders 
and causes decreased reward capacity upon withdrawal. 
Antidepressants share neither of those properties with 
amphetamine-like drugs. One would expect this. In order to 
function adaptively, the reward system must be stimulated only by 
actions and events that increase survival value to the organism or to 
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offsprir Thus, a hyperactive reward system would be as 
detrimen al to an animal as a hypoactive reward system; one could 
in fact view the condition of bipolar affective disorder as a cycling 
between the two extremes with an inability to maintain a proper 
level of reward capacity. Consistent with this paradigm is the ability 
of lithium to be effective both as an antidepressant and antimanic 
agent. One could view the effects of lithium as preventing the 
reward capacity from being too extreme to effectively modulate the 
behavior of the animal. 
Major reward pathways such as the medial forebrain bundle 
may not be directly affected by antidepressants. Since antidepres-
sants do not appear to cause dramatic changes in reward capacity rn 
normal animals, it is possible that they modulate the tone of the 
system in response to behavioral cues. They could do this by actions 
on pathways which indirectly affect major reward pathways. The 
affect of amphetamine in mood disorders may be akin to throwing 
gasoline on a running engine; rather than increasing performance, it 
is likely to cause an explosion. Likewise, a dramatic increase m 
catecholaminergic transmission could cause further instability m 
reward capacity that is detrimental to the animal. However, if a 
medication's effect on a system which enervated reward systems 
were to cause the system to function more evenly and to avoid 
extremes of reward capacity, it could have great therapeutic value. 
The ability of antidepressants to down regulate B-adrenergic 
receptors, decrease the sensitivity of a2-adrenergic receptors, and 
increase the sensitivity of a 1 -adrenergic receptors occurs temporally 
with their therapeutic effects (Kostowski et al., 1986) and may be 
involved in modulating catecholaminergic transmission and thus 
reward capacity. In order to observe a large effect of these 
medications on reward threshold in the rat, it may be necessary to 
disturb the system either by inesi::a;>a1-ik :t:e'.:s (Zacharko et al., 
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1984; Valentino and Dufresne, 1989), or by observing the interaction 
of a medication that directly affects reward systems such as 
amphetamine or morphine. In light of the proposition that 
antidepressants reverse or prevent abnormally low reward capacity, 
effects of these medications on thresholds following 
catecholaminergic depletion by reserpine, tetrabenazine, or chronic 
amphetamine administration followed by withdrawal would be quite 
large, whereas a medication such as lithium might be useful in 
modifying both the effects of agents that either increase or decrease 
thresholds. 
Similar interaction techniques. have been used in conjunction 
with the ICSS technique to examine the effect of depletion of 
neurotransmitters in reward. One example is in a study in which 
catecholamine depletion by alpha-methyl-para-tyrosine reversed 
morphine sulfate increases in rate of self-stimulation whereas the 
serotonin depleting agent para-chlorphenylalanine did not (Pert and 
Hulsebus, 1975). This study demonstrated the relative importance of 
dopamine and norepinephrine as compared to serotonin for 
morphine's effect on reward systems. Decreases in escape from 
aversive stimulation of the mesencephalic reticular formation by 
morphine were potentiated by the potent indirect catecholaminergic 
agonist d-amphetamine even though the low dose of d-amphetamine 
had no effect in this model (Sasson et al., 1986). Such techniques 
used to examine the pharmacological effects of analgesics could be 
used to understand the nature of antidepressant effects in reward 
systems. 
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Another potentially important factor in affective disease is the 
interplay between reward capacity and aversion capacity. A version 
capacity is the relative sensitivity of the animal to aversive stimuli 
that enables the animal to avoid detrimental situations. Electrical 
stimulation of brain areas involved with the aversion system causes 
the animal to attempt to escape or avoid the noxious stimulation in a 
similar manner as it would to an environmental punisher (Cooper 
and Taylor, 1967; Clarke and File, 1982). As reward capacity is 
critical to positive reinforcement and negative punishment, aversion 
capacity is necessary for negative reinforcement and positive 
punishment to occur. The most obvious example is the need of the 
animal to sense pain and thus avoid tissue damage. The indirect 
dopamine agonist d-amphetamine is a potent analgesic which does 
not require central endorphin activity for its effect (Drago et al., 
1984 ). Interestingly, the dopamine antagonist haloperidol as well as 
nalaxone inhibited the analgesic effects of morphine as well as d-
amphetamine, whereas nalaxone failed to inhibit d-amphetamine 
induced analgesia. It appears that dopamine is as critical to pain as 
it is to reward. 
Reward capacity and aversion capacity function in a reciprocal 
fashion. Rewarding electrical stimulation of the medial forebrain 
bundle of the lateral hypothalamus has been shown to reduce escape 
from aversive stimulation of the nucleus reticularis gigantocellularis 
(Carr and Coons, 1981). Agents which increase reward capacity, such 
50 
as morphine, d-amphetamine, or chlordiazepoxide, also decrease the 
escape or avoidance of aversive brain stimulation (Marcus and 
Kornetsky, 1974; Morato de Carvalho et al., 1981; Clarke and File, 
1982). In light of the numerous somatic complaints of depressed 
patients as well as the use of tricyclic antidepressants in chronic pain 
(Maciewicz and Martin, 1987), clinical evidence also seems to support 
this inverse relationship between aversion and reward. Also, chronic 
administration of desipramine has been shown to decrease the 
density of cortical opiate receptors; this finding supports an indirect 
effect of antidepressants on opiate systems (O'Neill, 1983). 
Decreased reward capacity increases apparent aversion capacity, and 
lessened aversion capacity seems linked to increased reward 
capacity. Thus, it may be necessary to monitor both reward and 
aversion threshold in investigating the mechanism of action of 
antidepressants and in the detection of future useful agents. 
The lack of pronounced effect of chronic treatment with 
antidepressants in lowering self-stimulation thresholds in the 
present study calls into question whether the critical effect of 
antidepressants is raising reward capacity or whether it is in 
restoring reward capacity to normal. This effect could either be 
direct or secondary to a decrease in aversion capacity. It is unlikely 
that the lack of effect of desipramine or fluoxetine on thresholds is 
due to insufficient dosage, as weight reduction and decreased motor 
activity is pronounced for these groups as compared with control. 
Also, the threshold technique we used accurately demonstrated the 
marked threshold lowering effects of 6 mg/kg of morphine sulfate 
(Fig. 31 ). It now appears more likely that antidepressants show a 
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large effect in preventing or reversing elevation of reward 
thresholds induced by environmental stressors. This theory 1s 
supported by the results of the study of Zacharko and associates 
(1984). As we have demonstrated in our lab, animal models of 
depression can be used to cause a persistent raising of reward 
thresholds (Valentino and Dufresne, 1989). The small effect seen 
with desipramine 10 and 20 mg/kg in this model may be related to a 
post surgery induced raising of thresholds due to the stressful nature 
of the experience. This is likely not a factor in the current study due 
to the extra three to four weeks required by the initial albuterol 
testing pnor to the chronic antidepressant phase. Also, it cannot be 
ruled out that the one time administration of albuterol or the 
difference in antidepressant dosing schedule may have affected 
response to the antidepressant. 
Effects of Antidepressants on Activity 
Acute effects 
Interest in the acute effects of antidepressant drugs on 
exploratory behavior and locomotor activity can be traced back to 
the lack of interest and psychomotor retardation predominant m 
major depressive syndrome. Separating the effects of 
antidepressants on spontaneous locomotor activity and on 
exploratory behavior is often difficult (File and Tucker, 1986), and it 
is unclear whether to do so is unrealistic as the two behaviors are 
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highly associated with one another. Some authors argue that the 
first minutes after being put in an open field an animal's activity 
mainly reflects exploration. Others argue that the activity of the 
animals .i.r. exploring mazes or tunnels is indicative of exploratory 
behavior and that this can be measured separately from the 
locomotor activity. Researchers use different paradigms as well as 
different time of measurement after entry into the open field or 
device. Therefore, comparisons among the different studies of 
antidepressants on locomotor activity and exploratory behavior can 
be difficult and often contradictory. However, some general 
conclusions can be drawn. 
In the present study the first fifteen minutes of activity in the 
open field is considered to be a combination of exploratory and 
motor behavior, whereas the second period reflects predominantly 
locomotor activity. The desipramine treated animals show a 
pronounced decrement in ambulation (horizontal motor activity) and 
rearing for the first fifteen minute period whereas the fluoxetine 
treated animals only exhibited a decrease in rearing. For the second 
fifteen minute period the desipramine and fluoxetine groups had 
decreased ambulation whereas the saline group did not (Fig.19-22). 
There were no cases in which the antidepressants increased activity. 
These effects are consistent with the majority of the literature. 
Desipramine (10 mg/kg) and imipramine (10 mg/kg) but not 
nortriptyline (15 mg/kg) were shown to decrease ambulation 
acutely, while nortriptyline was shown to increase rearing acutely 
over two minutes in the open field (Kulkarni and Dandiya, 1973). In 
this study monoamine oxidase inhibitors pargyline and nialamide 
53 
decreased ambulation but had no effect on rearing. Przegalinski and 
associates (1983) demonstrated decreased a.mbulation and rearing 
over three minutes for 10 mg/kg of imipramine and desipramine, 
while fluvoxamine 10 mg/kg reduced onJ~r :1mbulation. Strangely, 
the sedating antidepressants amitriptyline and citalpram ( 10 mg/kg) 
had no effect on either. These studies looked at only the exploratory 
period of motor activity. Shillito (1970) saw similar decreases in 
exploratory behavior using a tunnel entry paradigm on the first day 
with imipramine 20 mg/kg, though on the second day of treatment 
an increase in exploratory behavior was observed. The monoamine 
oxidase inhibitors tranylcypromine and nialamide increased 
exploratory behavior in mice on both the first and second days of 
treatment. Interestingly, amphetamine 4 mg/kg and 8 mg/kg 
reduced exploratory activity but caused an increase in locomotion. 
In contrast, the second generation antidepressant bupropion 
given acutely (10 and 30 mg/kg) increases locomotor activity in rats 
in a dose dependent manner (Nielsen et al., 1986; Tucker and File 
1986). In a review of the effects of antidepressants on motor 
activity, Tucker and File (1986) observed that with the exception of 
amineptin, bupropion, and nomefensine all antidepressants tend to 
depress locomotor activity acutely. Amineptin, bupropion, and 
nomefensine are all antidepressants in which a dopaminergic 
mechanism of action has been implicated (Dufresne et al., 1984; 
Tucker and File, 1986). 
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Chronic Effects 
During the first fifteen minute activity period (Fig. 27 - 28) all 
groups exhibit decreases in ambulation (horizontal activity) and 
rearing. Thus, exploratory activity does not differ between 
antidepressant and control groups over the course of the study. 
However, results for the second fifteen minute period of locomotor 
activity show decreased ambulation (Fig. 29) for desipramine and 
fluoxetine, but not for the saline treated animals. Similarly, rats 
administered desipramine and fluoxetine show decreases in rearing 
activity during the second fifteen minute period (Fig. 30) as 
compared to control. These were most pronounced between days 
four and eleven. Thus, chronic treatment with both desipramine and 
fluoxetine causes greater decreases in spontaneous locomotor activity 
than controls over time, but neither antidepressant group shows 
differences in exploratory activity. 
The lack of effect of chronically administered desipramine on 
exploratory activity as compared with control is dissimilar from the 
increase in ambulation seen with the agent in the study of 
Przegalinski and associates (1983) and the decrease after fifteen 
days of treatment seen by Kulkarni and Dandiya (1973). Long-term 
treatment with fluvoxamine, an antidepressant similar chemically 
and pharmacologically to fluoxetine (Mendels, 1987; Doogan, 1980), 
has been shown to decrease exploratory ambulation and rearing 
(Przegalinski et al., 1983). The results of a study of the effects of six 
days of treatment with imipramine or chlorimipramine on 
exploratory activity in the rat were similar to those of this study m 
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that there were no significant differences with control in exploratory 
ambulation as measured by tunnel entries and for rearing (Harrison-
Read and Steinberg, 1980). 
Th~ decrease in both ambulation and rearing seen in the 
present study is consistent with previous studies showing decreased 
spontaneous motor activity with most antidepressants (Tucker and 
File, 1985). The decrease in ambulation and rearing as compared 
with control was most evident between day 11 and day 18. This 
result does not fit with a pattern of early sedation, and is apparently 
a result of chronic treatment with the antidepressants. This could be 
the result of pharmacodynamic changes due to chronic antidepres-
sant treatment or could partially reflect the five days or more 
needed to reach peak plasma concentrations of antidepressant. These 
effects on ambulation and rearing occur during the same time period 
in which antidepressants first show their clinical effects. 
Effects of Albuterol Prior to Antidepressant 
Effects on Thresholds 
Increases in mean and ascending thresholds was observed on 
administration of the B-agonist albuterol to the naive rats (Fig. 1-2). 
Thresholds immediately returned to baseline after the test day. The 
most pronounced effect was on ascending thresholds. The increase rn 
thresholds , and thus the decrease in reward capacity , is consistent 
with the study of Liebman and associates (1984) in which they used 
a rate technique to study B-agonist effects . They found that the B2 -
agonists clenbuterol, albuterol, and terbutaline decrease rate of 
response for current levels at the lower end of their animals 
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response curve. They also found that these effects were reversed by 
the non-selective B-antagonist propranolol. However, since these B-
agonists also caused a pronounced decrement in spontaneous motor 
activity, it is difficult to separate the effect of reduced motoric 
performance on lever pressing from the reward capacity of the 
animal. Since the threshold technique in the present study is 
theoretically free of performance confound, this is the first study to 
show unequivocally that the B2-agonist albuterol raises reward 
thresholds in the rat. As there are instances in this study where 
decreased motor activity is not associated with change in threshold, 
it is apparent that the threshold technique is free from performance 
confound in reality as well as in theory. 
An interesting finding of the Liebman and associates study 
(1984) is that the potent B2-agonist clenbuterol failed to affect 
thresholds in animals with high baseline activity . As animals with 
high baseline activity levels were receiving current well above their 
thresholds, and the low baseline animals were probably receiving 
current not far above their thresholds, it is apparent that there is a 
current level where an animal wiIJ respond no matter how the 
reward system is compromised. This is consistent with the findings 
of Fibiger and Phillips (1981) , who failed to see differences at the 
extremes of the dose response curve even though there was a 
pronounced difference between treatment groups at the middle 
levels of current intensities. 
An important implication of the decrease in reward capacity 
caused by B2-adrenergic agonists is its consistency with the B-
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adrenergic receptor down regulation theory of depression. The B-
adrenergic agonist effect results in increased activity in these 
systems as would likely occur due to supersensitivity in these 
systems m major depression. Since overactivity of B-adrenergic 
systems is associated with dysphoria, it is understandable that a 
decrease in B-receptor sensitivity would be therapeutic. In light of 
the reported selective actions of albuterol on B2-adrenoceptors, it is 
tempting to speculate that these receptors may have an important 
role in depressive disorders. 
Another important finding of the Liebman et al. (1984) study is 
that the self-stimulation rate lowering effects of clenbuterol (0.3 
mg/kg) and albuterol ( 1 and 10 mg/kg) disappear after 3 days of 
treatment. This rapid tolerance is not seen with clonidine (0.3 
mg/kg), which also decreases rate of ICSS responding to 20 percent 
of controls. The persistent effect of clonidine, an a2-agonist at low 
doses and an a 1-agonist at higher doses, on reward capacity is 
interesting in light of the effects of many antidepressants on a -
adrenergic receptors. Desipramine has been shown to cause 
subsensitvity of a2-adrenergic receptors in rat brain (Crews and 
Smith, 1978; McMillen et al., 1980). Yohimbine, an a-adrenergic 
antagonist with some selectivity for a2-receptors, has been shown to 
potentiate the activity of anti.depressants in the behavioral despair 
model (Zebrowska-Lupina, 1980) and many other animal models of 
depression (Malick, 1981 ). 
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Effects on Motor Activity 
Albuterol caused a pronounced decrease m exploratory and 
spontaneous ambulation and rearing (Fig. 3-6). For all but 
exploratory ambulation there was a return to baseline values by two 
days after albuterol administration. This A-B-A return to baseline 
design reveals a 60 percent decrement in ambulation for both 
periods with albuterol and a greater than 35 percent drop in rearing 
for both periods. This is similar to the large decrease in motor 
behavior seen by Liebman et al. (1984) for the B2-agonists albuterol, 
clenbuterol, and terbutaline and also by Mogilnicka (1982) for 
albuterol. All effects of the B2 -adrenergic agonists were reversed by 
propranolol, and tolerance to the motor effects of clenbuterol 
developed by the end of a four day treatment period (Liebman et al., 
1984 ). Prezegalinski and associates (1983) have observed albuterol 
induced decreases in exploratory ambulation to as little as only 20 
percent of control. 
Therefore, B2-agonists cause pronounced decreases in both 
exploratory and spontaneous motor activity. Overactivity of B-
adrenergic neurosystems as caused by these B2-adrenergic agonists 
may be analogous to that seen due to supersensitive B-adrenergic 
receptors in depression. This would be consis tent with the 
psychomotor retardation that is a frequent symptom of depressive 
disorders. Interestingly, the B-antagonist propranol given acutely 
has been shown to reduce rat immobility in the Porsolt behavioral 
despair model in the same manner as antidepressants; clonidine also 
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showed this property (O'Neill, 1983). Propranol given acutely would 
cause immediate reversal of overactive B-adrenergic systems. 
Clonidine causes reduction in immobility in the Porsolt model 
via an a-adrenergic agonistic mechanism; it is unclear whether the 
activity on a 1 or a2-adrenergic receptors is critical. The a-
adrenergic antagonist yohimbine, like propranolol, has been shown to 
reverse albuterol induced hypoactivity in the rat (Mogilnicka, 1982). 
Thus, the a-adrenergic antagonists consistently act as the B2-agonists 
and the a-adrenergic agonists act in the manner of the B-adrenergic 
antagonist. A functional relationship between these 
neurotransmitter systems seems likely with regard to motor activity 
and perhaps reward capacity. 
Effects of Albuterol After Chronic Administration of 
Antidepressant 
Threshold effects 
Both desipramine and saline treated animals show increases in 
mean threshold in response to albuterol while the fluoxetine treated 
animals do not (Fig. 7). Thus, chronic treatment with fluoxetine 10 
mg/kg apparently causes decreases in sensitivity to the B2-
adrenergic antagonist that differs from the effects of both saline and 
desipramine 10 mg/kg. As both the fluoxetine and desipramine 
groups show pronounced weight loss as compared with control over 
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the course of the study, the difference is not due to lack of sufficient 
treatment with desipramine. 
A similar trend is evident for the descending and ascending 
thre~holds that fails to reach significance (Fig. 8-9). It is likely that 
the relatively low power of the between group comparisons in this 
design decreased the sensitivity of the analysis for the separate 
indices. However, the mean threshold is a combination of the two 
indices and is therefore more reliable. The increase in reliability for 
the mean threshold decreased the error of measurement sufficiently 
for the similar difference to be statistically significant. 
The increase in mean threshold upon albuterol administration 
for the desipramine and saline treatment groups persists for at least 
one week; this is dissimilar to the effects of albuterol prior to 
antidepressant treatment. While it is possible that withdrawal from 
desipramine could be responsible for this effect, it is unlikely since 
the saline treated animals also demonstrated a persistent increase in 
thresholds. The only systematic difference between the post-
albuterol saline treatment days prior to and after antidepressant 
treatment is that the animals were used to receiving the nightly 
injection of antidepressant or vehicle for the three week period pnor 
to the terminal albuterol challenge. However, the lack of any 
changes in threshold for the fluoxetine treated animals would argue 
against this confound. Thus, the best explanation for this phenomena 
is a differing effect on B-adrenergic receptors for desipramine and 
fluoxetine. 
It is reasonable to infer that the selective effects on 
serotonergic mechanisms by fluoxetine is responsible for the lack of 
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reactivity of this group to the albuterol challenge. Fluoxetine is very 
specific in inhibiting serotonin reuptake and js devoid of affi nity for 
histaminic, muscarinic, 5-HT-1 or 5-HT-2, or either al or a 2-
adrenergic receptors (Stark et al., 1985) . The innervation of B2-
adrenergic receptors in the cerebral cortex is currently unknown; B1 
receptors are neuronally innervated by norepinephrine (Minneman 
et al., 1981 ). It is tempting to speculate that serotonergic systems 
innervate the B2-adrenergic receptors in cerebral cortex. 
There is increasing evidence that antidepressants cause a 
down-regulation of a linked 5-HT/norepinephrine B-adrenoceptor 
system, and that impairment of normal functioning of serotonergic 
neurons prevents this down-regulation even by non-serotonergic 
antidepressants such as desipramine (Sulser, 1987). Serotonergic 
mechanisms have been shown to be necessary for B-adrenergic 
down-regulation by imipramine (Dumbrille-Ross and Wang, 1983 ). 
Fluoxetine, which selectively blocks 5-HT reuptake, has been shown 
to down regulate B2-adrenergic receptors in several brain regions 
(Wamsley et al., 1987). 
Noradrenergic and serotonergic neurosystems appears to be 
interdependent. The a2-adrenergic agonist clonidine has been 
shown to reduce the electrically evoked release of 3 H-5-HT from rat 
brain cortical slices (Grob et al., 1987). Also, the B2-adrenergic 
agonists albuterol and clenbuterol have been shown to potentiate 5-
HT mediated behaviors induced by the serotonergic agon ist 
quizapine (Cowen et al., 1982; Green et al. , 1984), and clenbuterol 
was demonstrated to increase 5-HT turnover (Green et al., 1984 ). 
Interestingly, the clenbuterol induced potentiation of 5-HT mediated 
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behaviors and increase in 5-HT turnover was antagonized by the 
centrally acting B 1 -adrenergic selective antagonist metoprolol and by 
atenolol but not by the B2-adrenergic antagonist butoxamine (Cowen 
et al., 1982; Green et al., 1984); therefore, it is premature to link this 
effect on serotonergic systems to either B-adrenergic receptor 
subpopulation. 
Motor effects 
There were no differences in exploratory or spontaneous motor 
activity between animals chronically treated with desipramine or 
fluoxetine as compared with controls (Fig. 11-14). This differs from 
the results of the study of Przegalinki and associates (1983) who 
found that the antidepressants imipramine, desipramine, 
amitriptyline, fluvoxamine, and citalopram given orally at 10 mg/kg 
twice daily prevented albuterol (10 mg/kg I.P.) induced hypoactivity 
in rats. Our results may have differed with theirs due to the 
differences in dose and dosing schedule. Also, their study examined 
only ini_tial exploratory motor activity over three minutes, and their 
animals received the antidepressants :or 14 days rather than 19 
days. However, these differences in the two studies appear small, 
and it is difficult to understand why the results of the present study 
fail to replicate their findings . 
It is important to note that the difference in mean thresholds 
upon al buterol challenge between the fl uoxetine treated animals and 
the others is not mirrored m the results of the motoric variables. 
Similarly, the differences m spontaneous motor activity between 
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control and antidepressant group in the chronic antidepressant phase 
were not mirrored by raises in threshold. This is further evidence 
that the threshold technique ts not confounded by motoric 
impairment. 
Effects of Antidepressants Given Chronically on Weight 
Both fluoxetine and desipramine caused dramatic weight loss 
as compared to control (Fig. 26). Fluoxetine, a selective reuptake 
inhibitor of 5-HT, is likely to have caused this through a serotonergic 
mechanism. The 5-HT reuptake inhibitor and releaser 
dextrofenfluramine, used clinically in treating obesity and possibly 
effective in treating seasonal affective disorder (O'Rourke et al., 
1987), has been shown to be anorexigenic in rats (Chaouloff et al., 
1989). Dextrofenfluramine has also been shown to decrease rate of 
self stimulation of feeding centers in the lateral hypothalamus in rats 
(McClelland et al., 1989). The antidepressant zimelidine is, like 
fluoxetine, a potent serotonergic reupt~ke inhibitor; it has been 
shown to decrease eating and drinking behavior in a dose dependent 
fashion in pigeons while the serotonin antagonist cyproheptadine 
antagonized this effect (Gonturkun et al., 1989). 
The weight loss caused by desipramine could be accounted for 
by at least two mechanisms. First, the stimulatory effect of 
norepineprine on feeding behavior is mediated by a2-adrenergic 
receptors located in the medial hypothalamus; a2-adrenergic agonists 
such a clonidine cause hyperphagia in rats, while a 1-adrenergic 
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blockers such as prazosm do not antagonize the stimulatory effect of 
norepinephrine on eating behavior (Leibowitz et al., 1988). Weight 
loss during chronic desipramine treatment in this study is possibly 
due to a decrease in cx2-adrenergic receptor sensitivity (Crews and 
Smith, 1978; Kostowski et al., 1986) which may have led to 
decreased caloric intake. Another possible contributing mechanism 
in rats could be an acute increase in interscapular brown adipose 
tissue activity in rats; B-adrenergic receptors are activated by 
norepinephrine to stimulate metabolism (Carlson, 1986). The 
increase in norepinephrine in the synapse caused by desipramine 
could be responsible for the weight loss via an increase in 
metabolism prior to B-receptor down-regulation, while cx2-adrenergic 
receptor subsensitivity could mediate decreased food intake and 
weight loss after the first week or drug administration. 
Conclusions 
The antidepressants desipramine and fluoxetine given at 
dosages of 10 mg/kg via lavage daily for nineteen days did not lower 
thresholds as compared with saline. The results of this study do not 
support the hypothesis that antidepressants alleviate depression by 
increasing reward capacity. There are plausible alternative 
hypothesis. For example, the rats tested were not originally 
dysphoric . Humans who are not suffering from depression are not 
reported to experience euphorogenic effects or even improvements 
in mood with antidepressants. Animals may have to be in a state of 
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abnormally decreased reward capacity for there to be an effect. 
Furthermore, antidepressants may act to prevent abnormally low 
levels of reward capacity without affecting normal reward capacity .. 
Als0, aversive systems may be involved. An increased tolerance to 
aversive stimuli may be the principal result of therapy with 
antidepressant medication. 
The hypothesis that B-adrenergic agonists should raise ICSS 
thresholds was confirmed. The B-adrenergic agonist albuterol caused 
an increase in mean threshold of self-stimulation. However, the 
hypothesis that chronic administration of the antidepressants 
des~pramine and fluoxetine would decrease B-adrenergic receptor 
sensitivity and cause a diminished response to albuterol was only 
partially supported. The animals treated for nineteen days with 
fluoxetine did not show an increase in threshold upon administration 
of albuterol whereas those treated with desipramine or equal 
amounts of saline vehicle over the same time period did show an 
increase m mean threshold upon albuterol administration. Thus, 
only the fluoxetine treated animals appeared less sensitive to 
albuterol induced changes m threshold. Also, the persistent 
elevation of thresholds of up to a week after albuterol challenge for 
the saline and desipramine treated animals leaves open the 
possibility that a non-specific effect such as withdrawal of the 
evening injections resulted in the change. However, the lack of such 
an occurrence for the fluoxetine treated animals argues against this 
interpretation. 
The last hypothesis stated that the threshold method that we 
have adapted from Kornetsky and associates is less sensitive to the 
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performance confound than the rate technique for measuring reward 
capacity. While we were able to show a decrease in motor activity 
without a concomitant increase in reward thresholds during 
treatment with antidepressants, the onlv major changes in reward 
capacity we observed were increases in threshold which occurred 
concomitantly with substantial decreases m motor activity. Thus, 
while these experiments demonstrated that motor activity can 
change without affecting thresholds, we were unable to prove that 
thresholds could change without a corresponding change in motor 
activity. The inability to do so is largely due to the lack of a 
threshold lowering effect of desipramine or fluoxetine. Future 
studies with drugs likely to lower thresholds for self-stimulation and 
decrease motor activity or to increase ICSS thresholds while 
increasing motor activity would be helpful in this regard. 
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Fig. 1. The effects of albuterol on mean thresholds 
in the pre-antidepressant period. Albuterol (10 mg/kg) 
given by lavage 30 minutes prior to testing at time zero 
caused a significant (p < .05) increase in mean thresholds. 
67 
+4 days 
-Ill 
-0 
> 
-
"O 
-0 
.c 
Ill 
Q.I 
"" 
.c 
E--
# 
3.3 
3.2 --0--
• 
3.1 
3.0 
2.9 
2.8 
-4 Days -2 Days ALBUTEROL +2 days 
Time (days) 
FIG. 2. The effects of albuterol on descending and 
ascending thresholds in the pre-antidepressant phase. 
Albuterol (10 mg/kg) given at time zero caused a 
significant increase in ascending thresholds (p < .01) 
but did not affect descending thresholds. 
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Fig. 3. The effects of albuterol on horizontal movement 
during the first fifteen minute period for the pre-
antidepressant period. Albuterol (lOmg/kg) given 
by lavage at time zero caused a significant (p < .01) 
decrease in activity. 
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Fig. 4. The effects of albuterol in the pre-antidepressant 
period on horizontal motor activity during the second 
fifteen minute period. Albuterol (10 mg/kg) 
given at time zero caused a significant decrease (p < .01) 
in activity. 
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Fig. 5. The effects of albuterol on the first fifteen minutes 
of rearing in the pre-antidepressant phase. Albuterol 
(lOmg/kg) given at time zero caused a significant (p < .01) 
decrease in rearing. 
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second fifteen minutes in the pre-antidepressant period. 
Albuterol (lOmg/kg) given at time zero caused a 
significant (p < .01) decrease in rearing. 
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but not fluoxetine treated animals. 
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Fig. 8. The effects of albuterol on descending thresholds 
in the post antidepressant phase. Albuterol (10 mg/kg) 
given at time zero was associated with increased thresholds. 
Drug group by time differences were not significant. 
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Fig. 9. The effects of albuterol on ascending thresholds 
in the post antidepressant phase. Albuterol (10 mg/kg) 
given at time zero was associated with an increase in 
threshold that did not differ between drug treatment 
groups. 
530 
510 
490 
470 
-7days -4days 
A DesipraminelOmg/kg 
a 
Fluoxetine 1 Omg/kg 
Saline 
-2days Albuterol +2 days +4days +7days 
Time (days) 
Fig. 10. The effects of albuterol on weight in the post 
antidepressant phase. A significant increase in weight 
was observed (p < .01) that was not related to drug 
treatment group or albuterol adminstration. 
76 
fl:) 
c 4000 
Q 
·-.... 
c.. 
::s 
""" 
""" ~ 
.... 
c 
.... 3000 
5 
crJ 
~ 
.t:J 
Q 
.... 
Q 
.c 2000 .. Desipramine l Omg/kg Q. 
Fluoxetine lOmg/kg 
a Saline 
-7 days -4 days -2 days A I bu te ro I +2 days +4 days + 7 days 
Time (days) 
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Albuterol (10 mg/kg) given at time zero was associated 
with significantly (p < .01) decreased activity for all 
drug groups. 
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Fig. 12. The effects of albuterol on the se~ond fifteen 
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Fig. 13. The effects of albuterol on rearing in the first 
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Albuterol at time zero was associated with a significant 
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Fig. 14. The effects of albuterol on rearing in the second 
fifteen minute period during the post antidepressant phase. 
Albuterol (lOmg/kg) given at time zero was associated 
with a significant (p < .01) decrease in rearing 
for all drug groups. 
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Fig. 15. The effects of acute administration of 
antidepressants vs. saline on mean thresholds. 
There were no changes over time or between groups. 
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Fig. 16. The effects of acute administration of 
antidepressants vs. saline on descending thresholds. 
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Fig. 17. The effects of acute administration of 
antidepressants vs. saline on ascending thresholds. 
There were no differences between groups or over time. 
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Fig. 18. The effects of acute administration of 
antidepressants vs. saline on weight. There 
were no differences between groups or over time. 
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antidepressant vs. saline on the first fifteen 
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desipramine (10/mg/kg) showed a significant 
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Fig. 20. The effects of acute administration of 
antidepressants vs. saline on the second fifteen minutes 
of horizontal activity. Desipramine and fluoxetine 
treated animals showed decreased (p < .05) activity 
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Fig. 21. The effects of acute administration of 
antidepressants vs. saline on the first fifteen 
minute period of rearing. Desipramine and fluoxetine 
treated animals showed significantly decreased (p < .05) 
rearing while the saline animals did not. 
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Fig. 22. The effects of acute administration of 
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Fig. 23. The effects of chronic administration 
of antidepressants vs. saline on mean thresholds. 
There was a significant (p < .01) increase in thresholds 
over time that was not different between groups. 
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Fig. 24. The effects of chronic administration of 
antidepressants vs. saline on descending thresholds. 
There was a significant (p < .01) increase in thresholds 
over time regardless of drug treatment group. 
90 
-c;ll 
-0 
> 
-
"C 
-0 
.c 
c;ll 
Q,j 
'"" .c 
E--
91 
4 
ta Desipramine 10 mg/kg 
• F1uoxetine 10 mg/kg 
a Saline 
3 
-4 Days -2 Days Day 2 Day 4 Day 7 Day 9 Day 11 Day 14 Day 16 Day 18 
Time (days) 
Fig. 25. The effects of chronic administration 
of antidepressants vs. saline on ascending thresholds. 
Thresholds increased significantly (p < .01) over time 
regardless of drug treatment group. 
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Fig. 26. The effects of chronic administration of 
antidepressants vs. saline on weight. Desipramine and 
fluoxetine treated animals lost while saline animals 
gained significant (p < .01) amounts of weight over 
the course of this study phase. 
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Fig. 27. The effects of chronic administration of 
antidepressants vs. saline on the first fifteen 
minutes of horizontal activity. A significant (p < .01) 
decrease in activity was observed regardless 
of drug treatment group. 
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Fig. 28. The effects of chronic administration of 
antidepressants vs. saline on rearing in the first 
fifteen minutes. Thresholds decreased significantly 
(p < .01) over time regardless of drug treatment group. 
fl) 
c 
0 
-s=;.. 
:s 
""' 
""' Q,j 
-c 
-
E 
cu 
Q,j 
.&:J 
0 
-0 
.c 
Q.. 
2000 
1000 
A Desipramine lOmg/kg 
Fluoxetine lOmg/kg 
a Saline 
-4 Dayi-2 Days Day 2 Day 4 Day 7 Day 9 Day 11 Day 14 Day 16 Day 18 
Time (days) 
Fig. 29. The effects of chronic administration of 
antidepressant vs. saline on the second fifteen minute 
period of horizontal activity. Activity decreased 
significantly (p < .01) over time for desipramine 
and fluoxetine but not for control animals. 
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Fig. 30. The effects of chronic administration 
of antidepressants vs. saline on rearing during 
the second fifteen minutes. Desipramine and fluoxetine 
treated animals demonstrated sign~ficantly decreased 
rearing as compared to controls. 
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as compared with control. 
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AffENDIX A 
Example of a Trial to Obtain an Intracranial Self-Stimulation 
Threshold 
FILE FOR PROJECT: RL23 4-18-88 
DATE IS: 04-19-88 
ID# GROUP +TRIALS NEGSEG FALSEP VOLTSEG 
23 5 8 0 1 6.2 
23 5 10 0 0 6 
23 5 10 0 0 5.8 
23 5 10 0 4 5.6 
23 5 10 0 0 5.4 
23 5 10 0 1 5.2 
23 5 9 0 1 5.0 
23 5 10 0 1 4.8 
23 5 10 0 0 4.6 
23 5 6 0 0 4.4 
23 5 5 0 2 4.2 
23 5 6 0 0 4.0 
Decending threshold ----- 3.9 
23 5 1 0 0 3.8 
23 5 1 2 0 3.4 
23 5 1 3 0 3.6 
23 5 5 3 0 3.8 
23 5 3 2 0 4.0 
Ascending threshold ----- 4.1 
23 5 8 3 0 4.2 
1 1 5 
23 5 IO 2 I 4.4 
Legend: ID# is animal identification, Group is study condition 
designation, +TRIAL is the numb~r of r~~p0;1~es out of I 0 times when 
the rewarding electrical stimulation is available, NEGSEGS is the 
number of times an animal fails to respond at least 5 of ten times , 
F ALSEP is the number of pressess when current is not available, and 
VOL TSEG is the voltage available for the segment. For this run, the 
descending thteshold is 3.9 volts, the ascending threshold is 4.1 volts, 
and the mean threshold is 4.0 volts. 
APPENDIX B 
line re8dings 
Thresholds do not di ff er 
by more than 0.4 vol ts 
581ine dDily 
RDts are given 1 O mg/kg of 
albuterol via gastric lavage. 
Saline given unt 11 
there are three stab 1 e 
baselines. 
Rats ore given acut e 
dose of fl uoxet i ne .. 
desipromine .. or 
saline 30 minutes 
prior to testing_ 
Rots ore given desipromine .. 
fluoxetine .. or saline via gastric 
1 avoge for 19 doys at 6 p.m. ot o 
dose of 1 O mg/kg dai 1 y. 
All animals are wash-
ed out for 48 hours; 
Then 011 ore given 
o 1butero1 1 o mg/kg 
vi a gastric 1 ovage_ 
Three soli ne test periods. 
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